Obagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

Rhea-AI Summary

Obagi Medical (NASDAQ: WALD) announced a collaboration with Schweiger Dermatology to run the ALOHA Program, launching a Phase 4 clinical study and a real-world evaluation to generate post‑approval evidence for Obagi® saypha® MagIQ™. Initial activities are expected to begin in early 2026.

The program aims to translate pivotal trial safety and efficacy into everyday practice across Schweiger’s national network and present findings internally and at industry conferences.

Key Figures

Study phase: Phase 4 Program start: 2026 Brand experience: 35+ years +2 more

5 metrics

Study phase Phase 4 Phase 4 clinical study of Obagi saypha MagIQ in ALOHA Program

Program start 2026 Initial ALOHA program activities expected to begin in early 2026

Brand experience 35+ years Obagi Medical experience in advanced skincare per company background

Publication year 2025 Scientific framework on HA filler technologies cited from Gels 2025; 11(7):487

Market recognition year 2024 Obagi cited as fastest-growing professional skincare brand in the U.S. in 2024

Market Reality Check

Price: $1.70 Vol: Volume 40,801 is below th...

low vol

$1.70 Last Close

Volume Volume 40,801 is below the 20-day average of 65,757 (relative volume 0.62). low

Technical Shares trade below the 200-day MA of 2.03 with the last price at 1.70.

Peers on Argus

Peers show mixed moves: SKIN up 6.81%, GROV up 1.6%, ACU up 1.18%, DSY down 6.67...

1 Up

Peers show mixed moves: SKIN up 6.81%, GROV up 1.6%, ACU up 1.18%, DSY down 6.67%, while EWCZ is flat. No clear sector-wide trend to frame this collaboration news.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	ALOHA collaboration	Positive	-2.3%	Partnered with It’s a Secret Med Spa to enroll ALOHA real-world program sites.
Feb 17	ALOHA data platform deal	Positive	+1.1%	Teamed with Aesthetic Record’s EMR platform used by over 9,000 clinics.
Feb 6	ALOHA collaboration	Positive	+3.5%	DermFx partnership to bring ALOHA real-world program into med spa practice.
Feb 5	ALOHA collaboration	Positive	-4.9%	Strategic collaboration with Moxie to run ALOHA real-world evidence initiative.
Feb 3	Product launch	Positive	+5.3%	Introduced new Lip Therapy protocol with two-step resurfacing and protection regimen.

Pattern Detected

Recent product and ALOHA collaboration news has led to mixed reactions, with both gains and selloffs despite broadly positive strategic updates.

Recent Company History

Over the past month, Waldencast has issued a series of Obagi Medical updates, including multiple ALOHA Program collaborations (with Moxie on Feb 5, DermFx on Feb 6, Aesthetic Record on Feb 17, and It’s a Secret Med Spa on Feb 25) plus a Lip Therapy launch on Feb 3. Price reactions ranged from a -4.92% move on the Moxie collaboration to a 5.26% gain on the Lip Therapy protocol, suggesting investors have reacted inconsistently to similar partnership and product expansion news.

Market Pulse Summary

This announcement extends Obagi’s ALOHA framework by adding Schweiger Dermatology for a Phase 4 stud...

Analysis

This announcement extends Obagi’s ALOHA framework by adding Schweiger Dermatology for a Phase 4 study and broad real-world evaluation of Obagi® saypha® MagIQ™ starting in early 2026. It builds on prior ALOHA collaborations and emphasizes evidence-based rollout using standardized protocols and data capture. Investors may watch for initial findings shared at internal meetings and conferences, as well as how this program complements Waldencast’s existing regulatory disclosures and earlier product launches in Obagi’s portfolio.

Key Terms

real-world evidence, hyaluronic acid, fda pivotal trials, injectable

4 terms

real-world evidence medical

"Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi"

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

hyaluronic acid medical

"Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program"

A naturally occurring molecule that acts like a tiny sponge, holding water in skin, joints and eyes to keep tissues plump and lubricated. Investors track products containing hyaluronic acid because they power large markets—such as skincare, injectable fillers, eye drops and wound treatments—so demand, regulatory approvals, manufacturing capacity and raw-material costs can meaningfully affect a company’s sales and profit outlook.

fda pivotal trials regulatory

"translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice"

Pivotal FDA trials are the main clinical studies designed to show whether a new drug or medical device works and is safe enough for regulatory approval; they are often the decisive evidence the agency relies on. Think of them as the final exam for a treatment — strong results can unlock market access and future sales, while failures can stop development and affect investor value.

injectable medical

"introducing this innovative injectable, and we have the clinical depth and scale"

A product described as an "injectable" is a medicine or vaccine formulated to be given by needle, syringe, or infusion rather than taken by mouth. For investors it matters because injectables often require specialized manufacturing, cold storage and trained staff to administer, which can raise costs, create supply-chain risks and form higher barriers to competitors—factors that influence a product’s price, market reach and long-term revenue potential.

AI-generated analysis. Not financial advice.

Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Schweiger Dermatology as a key partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program.

Schweiger will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs.

“This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to introducing this innovative injectable, and we have the clinical depth and scale to evaluate how trial data translates into real-world outcomes across our diverse patient base,” said Dr. David Goldberg, Director of Cosmetic Dermatology and Clinical Research at Schweiger Dermatology. “Our providers see thousands of patients daily for both medical and cosmetic needs. That volume and expertise matter. This is exactly the kind of collaborative work that advances aesthetic dermatology. Obagi’s focus on integrated protocols and real-world insights aligns closely with how we prioritize accessible, high-quality patient care.”

The ALOHA Program with Schweiger encompasses two complementary initiatives. A Phase 4 clinical study, led by Dr. David Goldberg at the Hackensack location, will evaluate Obagi^® saypha^® MagIQ™ through a structured research protocol with standardized data capture. In addition, a real-world evaluation program will give providers at select top-performing Schweiger aesthetic locations hands-on experience with the product and complete Obagi protocols, with the goal of driving patient satisfaction and strengthening provider-patient relationships. Initial program activities are expected to begin in early 2026.

Schweiger will present initial findings at upcoming internal leadership meetings, highlighting the benefits of the new protocols and product within the Schweiger network. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing this innovative injectable across Schweiger’s extensive practices.

“Partnering with Schweiger Dermatology is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, education, and integrated patient outcomes,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics.”

Obagi^® saypha^® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.

For more information about ALOHA, visit https://obagi-professional.com.

About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm^® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.

About Schweiger Dermatology
Schweiger Dermatology is a leading national dermatology practice, providing medical, cosmetic, and surgical dermatology, as well as allergy services through Schweiger Allergy. Built around the needs of patients, Schweiger is committed to delivering high-quality, personalized care while removing barriers to access. With a focus on convenience, timely appointments, and clinical excellence, the practice makes expert skin and allergy care easier to get—often within days, with same- and next-day appointments available. Learn more at https://www.schweigerderm.com/.

About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.

Media Contact:
obagi@behrmancesa.com

Source: Waldencast plc

¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)

FAQ

What did Obagi Medical (WALD) announce about the ALOHA Program on February 27, 2026?

Obagi Medical announced a collaboration with Schweiger Dermatology to run the ALOHA Program including a Phase 4 clinical study. According to Waldencast, the initiative pairs standardized research and real-world evaluation to assess Obagi® saypha® MagIQ™ across Schweiger’s national practices.

When will the ALOHA Program activities with Schweiger Dermatology begin for Obagi Medical (WALD)?

Initial program activities are expected to begin in early 2026. According to Waldencast, the start will include site activity at Schweiger locations and the Phase 4 study led from the Hackensack site to collect structured real-world data.

What does the Phase 4 study in the ALOHA Program evaluate for Obagi® saypha® MagIQ™ (WALD)?

The Phase 4 study will evaluate Obagi® saypha® MagIQ™ through a structured protocol with standardized data capture. According to Waldencast, Dr. David Goldberg will lead the study at the Hackensack Schweiger location to assess real-world safety and performance.

How will Schweiger Dermatology contribute to Obagi Medical’s (WALD) real-world evidence efforts?

Schweiger will provide access to a national network of aesthetic sites and high patient volume for hands-on evaluation. According to Waldencast, the partnership enables protocol training, provider use of the product, and internal and conference presentations of findings.

What are the key product features of Obagi® saypha® MagIQ™ highlighted in the announcement by WALD?

Obagi® saypha® MagIQ™ uses MACRO Core Technology to create a stable 3D hyaluronic acid matrix with high usable HA content and predictable swelling. According to Waldencast, the technology targets natural-looking results with consistent gel distribution and injection force.